Q-omics provides the consensus-scored TMEM225B profile across patient tissues and cancer cell-line models. TMEM225B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TMEM225B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TMEM225B RNA expression shows 14,262 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where TMEM225B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM225B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM225B survival associations across molecular data types. TMEM225B RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM225B RNA expression–survival associations across cancer types. High TMEM225B expression shows unfavorable associations in UVM and KIRP, but favorable associations in BRCA, LAML, ESCA and COAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TMEM225B RNA expression.
This table summarizes TMEM225B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM225B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM225B shows lower tumor expression in KIRC, LUAD, UCEC, BRCA and KIRP and higher tumor expression in LIHC. The KIRC box plot shows higher TMEM225B RNA expression in normal versus tumor tissue (log2 FC = −0.330, t-test p < 0.001).
This table shows molecular features associated with TMEM225B in patient tissues and cancer cell lines. In patient samples, TMEM225B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM225B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
